Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Mets ace Kodai Senga faces hitters for the first time since his shoulder injuryMicrosoft will invest $1.7 billion in AI and cloud infrastructure in IndonesiaDecoding secrets behind the rise of China's NEVsWilliams, GilgeousA gunman kills 6 worshippers inside a Shiite mosque in western Afghanistan, the Taliban sayFrench screen legend Gerard Depardieu will go on trial for sexual assault in OctoberInjured Marlins leftCeltics' Porzingis leaves playoff game in Miami with right calf tightnessRays thwart Brewers' ninthBinance founder Changpeng Zhao faces sentencing; US seeks 3
2.773s , 6503.2421875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Stellar Series news portal